Prime Medicine
About Prime Medicine
Prime Medicine develops precision genetic medicines using its Prime Editing platform, a gene editing technology designed to correct disease-causing mutations at their source. The platform enables targeted 'search and replace' modifications within the genome while minimizing unintended DNA changes, addressing approximately 90% of known pathogenic genetic variants.
The company's pipeline spans multiple therapeutic areas including hematology, immunology, liver disease, pulmonary conditions, ocular disorders and neuromuscular diseases. Prime Medicine's approach focuses on delivering durable therapeutic outcomes by correcting genetic mutations rather than managing symptoms, positioning the company within the next generation of gene editing companies advancing beyond earlier CRISPR technologies.
Prime Medicine serves patients with rare genetic diseases where few effective treatment options exist. The company leverages its editing platform's versatility to develop both in vivo therapies delivered directly to patients and ex vivo therapies using edited cells. This dual-modality approach allows Prime Medicine to address a broad range of genetic conditions across different tissue types and delivery requirements.
Similar to Prime Medicine
More Companies →Why Prime Medicine Matters
Prime Medicine operates within the gene editing sector, where companies develop technologies to modify DNA sequences for therapeutic purposes. The field encompasses multiple editing modalities including base editing, prime editing and traditional CRISPR-Cas9 systems, each offering different precision and safety profiles. Gene editing represents a core technology area within biotechnology as companies work to address genetic diseases previously considered untreatable.
